3-amino-6-(1-aminoethyl)tetrahydropyrane derivatives

IPC classes for russian patent 3-amino-6-(1-aminoethyl)tetrahydropyrane derivatives (RU 2471795):

C07D519 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups ; C07D0453000000; or C07D0455000000

C07D513/04 - Ortho-condensed systems

C07D498/04 - Ortho-condensed systems

C07D471/04 - Ortho-condensed systems

C07D413/14 - containing three or more hetero rings

C07D405/06 - linked by a carbon chain containing only aliphatic carbon atoms

A61P31/04 - Antibacterial agents

A61K31/4709 -

A61K31/4375 -

Another patents in same IPC classes:

Oxazolidine antibiotics / 2470022

Claimed invention relates to derivatives of antibiotics, which represent compounds of formula (I) and their pharmaceutically acceptable salts, where U, V, W, X, R¹, R², R³, R⁴, R⁵, R⁶, A, B, D, E, G, m and n are determined in description. Invention also relates to pharmaceutical composition, containing said compounds and their application for obtaining medication for prevention or treatment of bacterial infections.

Anhydrous crystalline vinflunine salts, method for preparing and using them as drug, and method for purifying vinflunine / 2456291

Present invention refers to anhydrous crystalline vinflunine salts of general formula (I) prepared with 1 or 2 equivalents of a pharmaceutically acceptable inorganic or organic acid. . In formula (I) [The acid] represents hydrobromic, lactic or fumaric acid for a group of water-soluble crystalline salts, as well as para-toluenesulphonic, benzoic, mandelic and para-hydroxybenzoic acid for a group of relatively water-insoluble crystalline salts.

Azaindoles useful as janus kinase inhibitors / 2453548

Invention relates to novel azaindole derivatives, having JAK-2 and JAK-3 kinase inhibiting activity, or pharmaceutically acceptable salts thereof. In formula (I): R³ denotes H; X¹ denotes N or CR⁴; R² denotes H, COOH, COOR' or CONHR'; R⁴ denotes H, F, R, OH, OR', COR', COOH, COOR', CONH₂ or CN; or R² and R⁴, taken together, form a benzene ring optionally substituted with 1-2 R¹⁰; R' denotes C_1-3-alkyl or C_1-3-alkenyl, each optionally substituted 1-2 R⁵; each R⁵ is independently selected from CN, unsubstituted C_1-2alkyl, or two groups R⁵ together with a carbon atom with which they are bonded form a cyclopropyl ring; each R¹⁰ is independently selected from halogen, OCH₃ or OH; R¹ denotes or , R^” is H or denotes C_1-2alkyl, optionally substituted with 1-3 R¹¹; R⁶ denotes C_1-4alkyl, optionally substituted with 1-5 R¹²; values of radicals R⁷ -R⁹, ring A, R¹¹ -R¹⁴. The invention also relates to a pharmaceutical composition containing said compounds and a method of treating or reducing severity of a pathological condition such as allergy, asthma, amyotrophic lateral sclerosis, multiocular sclerosis, graft rejection, rheumatoid arthritis, solid malignant tumour, haematologic malignant disease, leukaemia, lymphoma and myeloproliferative disorders.

Substituted imidazopyridine derivatives as melanocortin-4 receptor antagonists / 2451684

Present invention relates to substituted imidazopyridine derivatives of general formula (I) or enantiomers, diastereomers and tautomers and pharmaceutically acceptable salts thereof, in which A denotes -NH-, -CH₂-, -CH₂-CH₂- or a bond; X denotes phenyl, phenyl condensed with a saturated heterocyclic 5- or 6-member ring, where the heterocyclic ring can contain one or two heteroatoms selected from O and N, and where the heterocyclic ring can further be substituted with an oxo group, a 6-member saturated heterocyclyl containing O as a heteroatom, a 5-6-member heteroaryl containing 1 or 2 heteroatoms selected from N, O and S, and where each phenyl and heteroaryl is possibly substituted with 1 to 2 R¹⁴ and/or 1 substitute R^4b and/or 1 substitute R⁵; R¹ and R² are independently selected from the following groups: C_1-6-alkyl and C₁-₆-alkylene-C_3-7-cycloalkyl, and where each alkyl is possibly substituted with a OH group, or R¹ and R² together with the nitrogen atom with which they are bonded form a 5-6-member ring which is possibly substituted with one substitute selected from C_1-6-alkyl and O-C_1-6-alkyl; R^4b denotes C(O)NH₂, C(O)OH, C(O)NH-C₁-₆-alkyl, C(O)N-(C₁.₆-alkyl)₂, SO₂-C_1-6-alkyl, oxo group, and where the ring is at least partially saturated, NH₂, NH-C_1-6-alkyl, N-(C_1-6-alkyl)₂; R⁵ denotes a 6-member heteroaryl containing N as a heteroatom; R³ denotes -(CR⁸R⁹)_n-T; R⁸ and R⁹ are independently selected from the following groups: H and C_1-6-alkyl; n equals 1, 2, 3, 4, 5 or 6; T denotes or NR¹²R¹³; R¹⁰ denotes H, NH₂, OH, C_1-6-alkyl, possibly substituted with one OH, a halogen atom, NH(C_1-6-alkyl) or N(C_1-6-alkyl)₂; q equals 1 or 2; Y denotes CH₂, NR¹¹ or O; R¹¹ denotes H, or C_1-6-alkyl; R¹² and R¹³ are independently selected from the following groups: H, C_1-6-alkyl, C_1-6-alkynyl, (CH₂)₀-₂-C_3-7-cycloalkyl, and C_1-6-alkylene-O- C_1-6-alkyl, where C_1-6-alkyl is possibly substituted with one halogen; R¹⁴ denotes a halogen atom, CN, C_1-6-alkyl, possibly substituted with 1-3 substitutes selected from halogen atom, OH, O- C_1-6-alkyl, O-C(O)C_1-6-alkyl, O- C_1-6-alkyl, possibly substituted with one substitute selected from OH, O- C_1-6-alkyl, and O-C(O) C_1-6-alkyl, or OH. The invention also relates to a pharmaceutical composition based on the compound of formula (I).

Indazoles, benzothiazoles, benzoisothiazoles, benzoisoxazoles, pyrazolopyridines, isothiazolopyridines, preparing and using them / 2450003

Present invention refers to organic chemistry, namely new compounds of formula , wherein A represents residues of formulae

Beta-lactamase inhibitors / 2445314

Present application describes substituted bicyclic beta-lactams of formula I: which are class A and class C β-lactamase inhibitors wherein X, R¹ and R² are specified in the application, as well as a method for producing them. The compounds of formula I and their pharmaceutically acceptable salts are applicable for preparing a pharmaceutical composition and for producing a drug. The declared compounds are applicable for treating bacterial infections, optionally in a combination with a β-lactam antibiotic. Particularly, the compounds may be used with such β-lactam antibiotics, as e.g. imipenem, piperacillin or ceftazidime to control microorganisms resistant to β -lactam antibiotics due to the presence of β-lactamases.

Pharmaceutical compounds / 2443706

Invention relates to compounds of formulae

Phosphoinositide-3-kinase inhibitors and pharmaceutical compositions containing said inhibitors / 2437888

Invention relates to compounds of formulae and including their stereoisomers, as well as pharmaceutically acceptable salt, where X denotes O or S; R¹ is selected from H, F, CI, Br, I, CN, -CR¹⁴R¹⁵-NR¹⁶R¹⁷, -CR¹⁴R¹⁵-NHR¹⁰, -(CR¹⁴R¹⁵)NR¹⁰R¹¹, -(CR¹⁴R¹⁵)_nNR¹²C(=Y)R¹⁰, -(CR¹⁴R¹⁵)_nNR¹²S(O)₂R¹⁰, -(CR¹⁴R¹⁵)_mOR¹⁰, -(CR¹⁴R¹⁵)_nS(O)₂R¹⁰, -C(OR¹⁰)R¹¹R¹⁴, -C(R¹⁴)=CR¹⁸R¹⁹, -C(=Y)OR¹⁰, -C(=Y)NR¹⁰R¹¹, -C(=Y)NR¹²OR¹⁰, -C(=O)NR¹²S(O)₂R¹⁰, -C(=O)NR¹²(CR¹⁴R¹⁵)_mNR¹⁰R¹¹, -NHR¹², -NR¹²C(=Y)R¹⁰, -S(O)₂R¹⁰, -S(O)₂NR¹⁰R¹¹, C₂-C₁₂ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₃-C₄ carbocyclyl, piperidinyl, thiopyranyl, phenyl or C₅-C₆ heteroaryl; R² is selected from H, C₂-C₁₂ alkyl and thiazolyl; R³ denotes a condensed bicyclic heteroaryl selected from indazole, indole, benzoimidazole, pyrrolopyridine, imidazopyridine and quinoline; R¹⁰, R¹¹ and R¹² independently denote H, C₂-C₁₂ alkyl, C₃ carbocyclyl, heterocyclyl selected from pyrrolidine, morpholine and piperazine, phenyl or heteroaryl selected from pyrazole, pyridine, benzothiophene; or R¹⁰ and R¹¹ together with a nitrogen atom with which they are bonded possibly form a saturated C₃-C₆ heterocyclic ring, possibly containing one additional ring atom selected from N or O, where said heterocyclic ring is possibly substituted with one or more groups independently selected from oxo, (CH₂)_mOR¹⁰, NR¹⁰R¹¹, SO₂R¹⁰, C(=O)R¹⁰, NR¹²S(O)R¹¹, C(=Y)NR¹⁰R¹¹, C₁-C₁₂ alkyl and heterocyclyl selected from pyrrolidine; R¹⁴ and R¹⁵ are independently selected from H or C₁-C₁₂ alkyl; R¹⁶ and R¹⁷ independently denote H or phenyl; R¹⁸ and R¹⁹ together with a carbon atom with which they are bonded form a C₃-C₂₀ heterocyclic ring, where said alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, phenyl, heteroaryl, piperidinyl and condensed bicyclic heteroaryl possibly substituted with one or more groups independently selected from F, CI, Br, I, CF₃, -C(=Y)R¹⁰, -C(=Y)OR¹⁰, oxo, R¹⁰, -C(=Y)NR¹⁰R¹¹, -(CR¹⁴R¹⁵)_nNR¹⁰R¹¹, -NR¹⁰R¹¹, -NR¹²C(=Y)R¹⁰, -NR¹²C(=Y)NR¹⁰R¹¹, -NR¹²SO₂R¹⁰, OR¹⁰, SR¹⁰, -S(O)₂R¹⁰, -S(O)₂NR¹⁰R¹¹, possibly substituted with carbocyclyl, selected from cyclopropyl, possibly substituted heterocyclyl selected from piperazine, possibly substituted with alkyl and alkylsulphonyl, pyrrolidine, morpholine, piperdine, possibly substituted CH₃, phenyl and possibly substituted heteroaryl selected from imidazole and triazole; Y denotes O; m equals 0, 1 or 2; n equals 1 and t equals 2. The invention also relates to a pharmaceutical composition which modulates lipid kinase activity, based on said compounds.

Novel compounds and use thereof / 2437887

Invention relates to compounds of formula where R¹ is selected from H, F, CI, Br, CF₃, C₁-C₆ alkoxy and OH; R² is selected from H and C₁-C₆ alkyl; n equals 1-5; m equals 0 or 1; and Y is selected from CH₂, NR³, (NR³R⁴)⁺X^-, O and S; R³ and R⁴ are independently selected from H and C₁-C₄ alkyl; and X^- is selected from pharmaceutically acceptable anions. The invention also relates to a method of producing said compound and to an antiviral pharmaceutical composition based on said compound of formula (I).

Novel heterocyclic compound or salt thereof and intermediate compound thereof / 2434868

Described is a compound of general formula: [1], where R¹ denotes an optionally substituted C₂-C₁₂ alkyl, aryl or heterocyclic group which can be a mono- or bicyclic 5-11-member radical, where the heteroatoms can be nitrogen, oxygen or sulphur; X¹ denotes C₂-C₄ an alkylene group; X² denotes a bond; X³ denotes a group of general formula NR³ or CR⁴R⁵NR³ (where R³ denotes a hydrogen atom, optionally substituted lower alkyl group or imino-protective group) and R⁴ and R⁵ are identical or different, and each denotes a hydrogen atom or a lower alkyl group or bond; X⁴ denotes a lower alkylene or lower alkenylene or lower alkynylene group, which can be substituted with one or more oxo groups or a bond; X⁵ denotes a sulphur atom or bond; Y¹ denotes an optionally substituted divalent 4-, 5- or 6-member alicyclic hydrocarbon residue or an optionally subsituted divalent 5- or 6-member alicyclic amine residue, where the heteroatoms can be nitrogen or oxygen; Z¹, Z², Z³, Z⁴, Z⁵ and Z⁶ are identical or different, and each denotes a nitrogen atom or a group of general formula CR⁷ (where R⁷ denotes a hydrogen atom, a halogen atom, a hydroxyl group, a cyano group, an optionally substituted amino group, or an amino group substituted with one or more C_1-6 alkyl groups, a lower alkyl group, a cycloalkyl, a lower alkoxy group or a monocyclic 5-member heterocyclic group which can be substituted with one or more halogen atoms, where the heteroatoms can be nitrogen, acid or sulphur or a group of general formula Q¹CO₂R¹⁰ (where R¹⁰ denotes a carboxyl-protective group and Q¹ denotes a lower alkenylene group), provided that at least one of Z³, Z⁴, Z⁵ and Z⁶ denotes a nitrogen atom, or salt thereof. The invention also describes an antimicrobial agent based on said compound.

Compositions for activation of lipoprotein lipase containing benzene derivatives / 2466725

Invention refers to an agent for activation of lipoprotein lipase containing a benzene derivative of general formula (1) which is used for preventing and treating hyperlipidemia and obesity. The invention also refers to the benzene derivatives of general formula (1a).

Method of producing diamine derivative / 2464271

Method is realised by mixing a compound of formula (B) with p-toluenesulphonic acid or a monohydrate of toluenesulphonic acid in less than 1 molar equivalent with respect to the compound of formula (B), in a solvent while heating. An additional amount of p-toluenesulphonic acid or monohydrate of p-toluenesulphonic acid is then added to the mixed solution while cooling in such an amount that their total molar equivalent with p-toluenesulphonic acid or monohydrate of p-toluenesulphonic acid at the mixing step is equal to 1 molar equivalent or more with respect to the compound of formula (B). At the last step, the obtained solution is crystallised to separate a compound of formula (A).

Pyrrolo- and thiazolopyridine compounds (versions) and based pharmaceutical composition / 2461557

Invention describes the pyrrolo- and thiazolopyridinium compounds and their pharmaceutically acceptable salts covered by general structural formula I: wherein the values A, B, R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are those as presented in cl.1, and a pharmaceutical composition based on the given compound for inhibition of hypoxia-inducible factor (HIF) hydroxylase activity.

Glucokinase activators / 2457207

Invention relates to compounds of formula I , and pharmaceutically acceptable salts thereof, where L denotes O, S, or CH₂; Y denotes N or CH; Z denotes CR₃; G denotes CH; R¹ denotes a heteroaryl ring of formula , where D¹ denotes S, O; D² denotes N or CR¹²; D³ denotes CR¹²; R² denotes (C₆-C₁₀)-aryl; 5-9-member mono- or bicyclic heteroaryl with 1 or 2 heteroatoms independently selected from N or S; a saturated or partially saturated (C₃-C₇)-cycloalkyl; or a saturated 5-6-member heteocyclyl with 1 heteroatom selected from N, where said aryl, heteroaryl, cycloalkyl and heterocyclyl are optionally substituted with one or two groups independently selected from (C₁-C₆)-alkyl, F, Cl, Br, CF₃, CN, NO₂, OR⁶, C(-O)R⁶, C(=O)OR⁶, C(=O)NR⁶R⁷, saturated 6-member heterocyclyl with 2 heteroatoms independently selected from N or O, and S(O)₂R⁶, and where said alkyl is optionally substituted with one -OR⁸ group; R³ denotes H; (C₁-C₆)-alkyl; (C₂-C₆)-alkenyl; Cl; Br; OR⁶; SR⁶; phenyl; or a 6-member heteroaryl with 1 heteroatom selected from N, where said alkyl and alkenyl are optionally substituted with one group selected from C(=O)OR⁸, -OR⁸, -NR⁸R⁹; or a saturated 6-member heterocyclyl with 1 heteroatom selected from N or O.

Benzotriazole uv-absorbers, having absorption spectrum shifted towards long-wave side, and use thereof / 2455305

Described are novel benzotriazole UV-absorbers, having absorption spectrum shifted towards the long-wave side with considerable absorption in the region up to 410-420 nm, having general formulae (a)-(k) (structural formula and values of radicals are given in the description), composition which is stabilised with respect to UV radiation and containing novel UV-absorbers, and use of the novel compounds as UV light stabilisers for organic materials.

Hiv-inhibiting 5-(hydroxymethylene- and aminomethylene)substituted pyrimidines / 2452737

Invention relates to novel substituted pyrimidine derivatives, having HIV replication inhibiting properties, or pharmaceutically acceptable salts thereof. In formula (1): R¹ denotes hydrogen; R² and R³ independently denote hydrogen; R⁷ and R⁸ denote C_1-6alkyl; R⁴ denotes cyano; R⁹ denotes C_1-6alkyl optionally substituted with cyano, C_2-6alkenyl substituted with cyano, C_2-6alkynyl optionally substituted with cyano; R⁵ denotes C_1-6alkyl optionally substituted with Ar or Het; C_2-6alkenyl optionally substituted with Ar or Het; C_2-6alkynyl optionally substituted with Ar or Het; C_3-7cycloalkyl; Ar; Het; R⁶ denotes H, Het; Y denotes -OR¹¹, -NR¹²R¹³; R¹¹ denotes hydrogen or C_1-6alkyl optionally substituted with hydroxy, C_1-6alkoxy or pyridyl; R¹² denotes hydrogen or C_1-6alkyl; R¹³ denotes hydrogen or C_1-6alkyl; or R¹² and R¹³ together with a nitrogen atom, which is substituted by said two substitutes, form a morpholinyl; imidazolyl; X denotes -NR¹-; Het denotes 5- or 6-member completely saturated ring, where one or two ring members are heteroatoms, each independently selected from nitrogen and sulphur, and where the rest of the ring members are carbon atoms; and where any member of the heterocycle with a nitrogen heteroatom can optionally be substituted with C_1-6alkyl; where the 5- or 6-member ring can optionally be annelated with a benzene or thiophene ring; each aryl independently denotes phenyl or phenyl substituted with one substitute selected from C_1-6alkoxy.

Substituted imidazo{2,1-b}thiazoles and application thereof for making drug preparations / 2450010

There are described substituted imidazo[2,1-b]thiazoles of general formula the R¹, R¹, R³ R⁴, M¹, M² radical values are presented in the patent claim cl. 1, as well as methods for making them, drug preparations containing these compounds and application of these compounds for making the drug preparations.

Indoles as 5-ht₆ modulators / 2449990

Invention refers to new compounds of formula

3,7-dithia-1,5-diazabicyclo[3,3,0]octane - fungicidally active agent / 2448971

Invention relates to novel agents for controlling plant fungal diseases, specifically 3,7-dithia-1,5-diazabicyclo[3,3,0]octane as an agent against Bipolaris sorokiniana, Aspergillus fumigates, Aspergillus niger, synthesis of which takes place in a single step using readily available reactants in contrast to multi-step synthesis of existing agents used for controlling fungal diseases of plants and materials.

Novel heteroaryl-substituted benzothiazoles / 2448106

Invention relates to a novel heteroaryl-substituted derivative of benzothiazole - 2-[6-(methylamino)pyridin-3-yl]-1,3-benzothiazol-6-ol where one or more atoms may be a detectable isotope, in form of a free base or pharmaceutically acceptable salt thereof, capable of binding with amyloid deposits, to pharmaceutical compositions based on the radioactive-labelled disclosed compound, to use of the detectable isotope-labelled disclosed compound for determining amyloid deposits, as well as use of the disclosed compound in producing a medicinal agent for preventing and/or treating Alzheimer's disease and familial Alzheimer's disease. The present invention also relates to a novel intermediate compound for producing the disclosed heteroaryl-substituted benzothiazole derivative

Production and use of substituted dihydro- and tetrahydrooxazolo-pyrimidinones / 2470937

Invention relates to novel 2-substituted-2,3-dihydrooxazolo[3,2-a]pyrimidin-7-ones and 2-substituted-2,3,5,6-tetrahydrooxazolo[3,2-a]pyrimidin-7-ones of formula (I): where p, n, X, Y, R₁, R₂, R₃, R₄, R₅, R₆, R₇ and R₈ are described in the description. These compounds are modulators of metabotropic glutamate receptors (mGluR), particularly the mGluR2 receptor. Compounds in the present invention are therefore suitable for use as pharmaceutical agents, especially in treating and(or) preventing various disorders of the central nervous system (CNS), including, among others, acute and chronic neurodegenerative disorders, psychosis, convulsions, anxiety, depression, migraine, pain, sleep disorder and emesis.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new antibacterial compounds of formula I

wherein R¹ represents halogen or alkoxy group; each U and W represents N; V represents CH, and R² represents H or F, or each U and V represents CH; W represents N, and R² represents H or F, or U represents N; V represents CH; W represents CH or CR^a, and R² represents H, or also when W represents CH, may represent F; R^a represents CH₂OH or alkoxycarbonyl; A represents group CH=CH-B, a binuclear heterocyclic system D, phenyl group which is mono-substituted in the position 4 by C_1-4 alkyl group, or phenyl group which is di-substituted in positions 3 and 4 wherein each of two substitutes is optionally specified in a group consisting of C_1-4 alkyl and halogen; B represents mono- or di-substituted phenyl group wherein each substitute is a halogen atom; D represents group

wherein Z represents CH or N, and Q represents O or S; or to salts of such compounds.

EFFECT: compounds are used for treating bacterial infections.

13 cl, 2 tbl, 25 ex

The text descriptions are given in facsimile form.

1. The compound of the formula I

where R¹represents a halogen or alkoxygroup;
U and W each represent N, V represents CH and R²represents H or F, or
U and V each represent CH, W pre is is a N and R ²represents H or F, or
U represents N, V represents CH, W represents CH or CR^aand R²represents H or, when W represents CH, can represent F;
R^arepresents CH₂HE or alkoxycarbonyl;
And represents the group CH=CH -, binuclear heterocyclic system D, a phenyl group which is mono-substituted in position 4
With_1-4alkyl group, or phenyl group which is di-substituted in positions 3 and 4, where each of the two substituents independently from each other selected from the group including_1-4alkyl and halogen;
Represents a mono - or di-substituted phenyl group, where
each Deputy is a halogen atom;
D is a group of

where Z represents CH or N, and
Q represents O or S;
or a salt of such compounds.

2. The compound of formula I according to claim 1, where, if U represents N and V represents CH, then W represents CR^aand R²represents H;
or a salt of such compounds.

3. The compound of formula I according to claim 1, which is also a compound of the formula I_CE

where R¹represents a halogen or_1-4alkoxygroup;
U and W each is th is a N, V represents CH and R²represents H or F, or
U and V each represent CH, W represents N and R²represents H or F, or
U represents N, V represents CH, W represents CH or CR^aand R²represents H or, when W represents CH, can represent F;
R^arepresents CH₂HE or C_1-4alkoxycarbonyl;
And represents the group CH=CH -, binuclear heterocyclic system D, a phenyl group which is mono-substituted in position 4
C_1-4alkyl group, or phenyl group which is disubstituted in positions 3 and 4, where each of the two substituents independently from each other selected from the group including_1-4alkyl and halogen;
Represents a di-substituted phenyl group, in which each Deputy is a fluorine atom;
D is a group of
,
where Z represents CH or N, and
Q represents O or S;
or a salt of such compounds.

4. The compound of formula I according to claim 3, where, if U represents N and V represents CH, then W represents CR^aand R²represents H;
or a salt of such compounds.

5. The compound of formula I according to claim 1, where R¹represents a C_{1-4/sub> alkoxygroup;

or a salt of such compounds.}

_{6. The compound of formula I according to claim 1, where a represents the group CH=CH -;

or a salt of such compounds.}

_{7. The compound of formula I according to claim 1, where a represents a binuclear heterocyclic system D;

or a salt of such compounds.}

_{8. The compound of formula I according to claim 1, where a represents a phenyl group which is mono-substituted in position 4 With_1-4alkyl group, or phenyl group which is disubstituted in positions 3 and 4, where each of the two substituents independently from each other selected from the group including_1-4alkyl and halogen;

or a salt of such compounds.}

9. The compound of formula I according to claim 1, which is selected from the following compounds:
{(3R,6S)-6-[(1R)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-yl}-[3-(E)-(2,5-differenl)allyl]amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-yl}-[3-(E)-(2,5-differenl)allyl]amine;
{(3R,6S)-6-[(1R)-1-amino-2-(6-ftorhinolon-4-yl)ethyl]tetrahydropyran-3-yl}-[(E)-3-(2,5-differenl)allyl]amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-ftorhinolon-4-yl)ethyl]tetrahydropyran-3-yl}-[(E)-3-(2,5-differenl)allyl]amine;
6-({(3R,6S)-6-[(1R)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4 is-pyrido[3,2-b][1,4]thiazin-3-one;
{(3R,6S)-6-[(1R)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-yl}-[3-(E)-(2,5-differenl)allyl]amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-yl}-[3-(E)-(2,5-differenl)allyl]amine;
6-({(3R,6S)-6-[(1R)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1R)-l-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
methyl ester of 8-[(2R)-2-amino-2-{5-[(E)-3-(2,5-differenl)allylamino]tetrahydropyran-2-yl}ethyl]-2-methoxyaniline-5-carboxylic acid;
methyl ester of 8-[(2S)-2-amino-2-{5-[(E)-3-(2,5-differenl)allylamino]tetrahydropyran-2-yl}ethyl]-2-methoxyaniline-5-carboxylic acid;
8-((S)-2-amino-2-{(2S,5R)-5-[(E)-3-(2,5-differenl)allylamino]tetrahydropyran-2-yl}ethyl)-2-methoxyaniline-5-yl] methanol;
[8-((R)-2-amino-2-{(2S,5R)-5-[(E)-3-(2,5-differenl)allylamino]tetrahydropyran-2-yl}ethyl)-2-methoxyaniline-5-yl]methanol;
6-({(3R,6S)-6-[(1R)-1-amino-2-(3-fluoro-6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-the laminitis}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1R)-1-amino-2-(3-fluoro-6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1R)-1-amino-2-(3-fluoro-6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxy[l,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-yl}-(4-active compounds)amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-benzo[1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-yl}-(3-fluoro-4-methylbenzyl)amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-benzo[1,4]oxazin-3-one;
6-({(3S,6R)-6-[(1R)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}IU who yl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3S,6R)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3S,6R)-6-[(1R)-1-amino-2-(7-fluoro-2-methoxyquinoline-8-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(7-fluoro-2-methoxyquinoline-8-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1R)-1-amino-2-(7-fluoro-2-methoxyquinoline-8-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(7-fluoro-2-methoxyquinoline-8-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1R)-1-amino-2-(3-fluoro-6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-benzo[1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-benzo[1,4]oxazin-3-one;
or a salt of such compounds.

10. The connection according to claim 9, which is selected from the following compounds:
{(3R,6S)-6-[(1R)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-yl}-[3-(E)-(2,5-differenl)allyl]amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-yl}-[3-(E)-(2,5-differenl)allyl]amine;
{(3R,6S)-6-[(1R)-1-amino-2-(6-ftorhinolon-4-yl)ethyl]tetrahydropyran-3-yl}-[(E)-3-(2,5-differenl)allyl]amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-ftorhinolon-4-yl)ethyl]tetrahydropyran-3-yl}-[(E)-3-(2,5-differenl)allyl]amine;
6-({(3R,6S)-6-(1R)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
{(3R,6S)-6-[(1R)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-yl}-[3-(E)-(2,5-differenl)allyl]amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-yl}-[3-(E)-(2,5-differenl)allyl]amine;
6-({(3S,6R)-6-[(1R)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1R)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
methyl ester of 8-[(2R)-2-amino-2-{5-[(E)-3-(2,5-differenl)allylamino]tetrahydropyran-2-yl}ethyl]-2-methoxyaniline-5-carboxylic acid;
methyl ester of 8-[(2S)-2-amino-2-{5-[(E)-3-(2,5-differenl)allylamino]tetrahydropyran-2-yl}ethyl]-2-methoxyaniline-5-carboxylic acid;
8-((S)-2-amino-2-{(2S,5R)-5-[(E)-3-(2,5-differenl)allylamino]tetrahydropyran-2-yl}ethyl)-2-methoxyaniline-5-yl]methanol;
[8-((R)-2-amino-2-{(2S,5R)-5-[(E)-3-(2,5-differenl)allylamino]tetrahydropyran-2-yl}ethyl)-2-methoxyaniline-5-yl]methanol;
6-({(3R,6S)-6-[(1R)-1-amino-2-(3-fluoro-6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamine is}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1R)-1-amino-2-(3-fluoro-6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1R)-1-amino-2-(3-fluoro-6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one;
6-({(3R,6S)-6-[(1R)-1-amino-2-(3-fluoro-6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(3-fluoro-6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-yl}-(4-active compounds)amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxyquinoline-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-benzo[1,4]oxazin-3-one;
6-({(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]oxazin-3-one;
6-({(3S,6R)-6-[(1R)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-yl}-(3-fluoro-4-methylbenzyl)amine;
{(3R,6S)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-silts what about the}methyl)-4H-benzo[1,4]oxazin-3-one;
6-({(3S,6R)-6-[(1R)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one and
6-({(3S,6R)-6-[(1S)-1-amino-2-(6-methoxy[1,5]naphthiridine-4-yl)ethyl]tetrahydropyran-3-ylamino}methyl)-4H-pyrido[3,2-b][1,4]thiazin-3-one
or a salt of such compounds.

11. The compound of formula I according to one of claims 1 to 10 or its pharmaceutically acceptable salt as a medicine for the prevention or treatment of bacterial infections.

12. The use of the compounds of formula I according to one of claims 1 to 10 or its pharmaceutically acceptable salt to obtain drugs for prevention or treatment of bacterial infections.

13. The compound of formula I according to one of claims 1 to 10 or its pharmaceutically acceptable salt for the prevention or treatment of bacterial infections.